A new skin drug, which has independent intellectual property, will be introduced to the market by Guangdong Zhonghao Pharmaceutical Company as a key product. Reporter learns from National Health Technology Park that the new drug has passed psoriasis clinical experiment. It has been applied for new drug registration and expected to obtain production approval in 2018.
Zhonghao Pharmaceutical Company was founded by international top medical experts and investors organized by listed companies including Guanhao Biotech Company, with 50mn yuan of register capital. Zhonghao Pharmaceutical Company is engaged with research and development and production of new drugs in skin disease treatment. The company is now located in National Health Technology Park in Torch Zone.